TODD ROSENGART to Adenoviridae
This is a "connection" page, showing publications TODD ROSENGART has written about Adenoviridae.
Connection Strength
1.796
-
Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. Hum Gene Ther. 2013 Feb; 24(2):203-8.
Score: 0.312
-
Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state. J Thorac Cardiovasc Surg. 2004 Feb; 127(2):535-40.
Score: 0.169
-
Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg. 2000 Jan; 69(1):14-23; discussion 23-4.
Score: 0.127
-
Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999 Aug 03; 100(5):468-74.
Score: 0.123
-
Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg. 1998 Apr; 27(4):699-709.
Score: 0.112
-
In situ reprogramming to transdifferentiate fibroblasts into cardiomyocytes using adenoviral vectors: Implications for clinical myocardial regeneration. J Thorac Cardiovasc Surg. 2017 02; 153(2):329-339.e3.
Score: 0.101
-
Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector. Ann Thorac Surg. 1996 Aug; 62(2):425-33; discussion 433-4.
Score: 0.100
-
"Triplet" polycistronic vectors encoding Gata4, Mef2c, and Tbx5 enhances postinfarct ventricular functional improvement compared with singlet vectors. J Thorac Cardiovasc Surg. 2014 Oct; 148(4):1656-1664.e2.
Score: 0.085
-
Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats. Hum Gene Ther Clin Dev. 2013 Mar; 24(1):38-46.
Score: 0.079
-
Double-blinded, placebo-controlled, randomized gene therapy using surgery for vector delivery. Hum Gene Ther. 2012 May; 23(5):438-41.
Score: 0.075
-
Angiogenic pretreatment to enhance myocardial function after cellular cardiomyoplasty with skeletal myoblasts. J Thorac Cardiovasc Surg. 2007 Feb; 133(2):478-484.e2.
Score: 0.052
-
Alteration of splicing signals in a genomic/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy. Mol Ther. 2005 Oct; 12(4):716-24.
Score: 0.047
-
Homozygous deletion of early growth response 1 gene and critical limb ischemia after vascular ligation in mice: evidence for a central role in vascular homeostasis. J Thorac Cardiovasc Surg. 2004 Oct; 128(4):595-601.
Score: 0.044
-
Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial. Circ Cardiovasc Interv. 2024 05; 17(5):e014054.
Score: 0.043
-
Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol Ther. 2004 Jan; 9(1):67-75.
Score: 0.042
-
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol Ther. 2002 Aug; 6(2):287-97.
Score: 0.038
-
Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure. J Thorac Cardiovasc Surg. 2002 Jun; 123(6):1101-13.
Score: 0.038
-
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations. Am Heart J. 2021 11; 241:38-49.
Score: 0.035
-
Percutaneous endocardial transfer and expression of genes to the myocardium utilizing fluoroscopic guidance. Catheter Cardiovasc Interv. 2001 Feb; 52(2):260-6.
Score: 0.034
-
Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg. 1999 Oct; 230(4):466-70; discussion 470-2.
Score: 0.031
-
Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg. 1998 Jan; 115(1):168-76; discussion 176-7.
Score: 0.028
-
Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Ther. 1997 Jan 20; 8(2):215-27.
Score: 0.026
-
Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther. 1997 Jan 01; 8(1):99-109.
Score: 0.026
-
Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease. Hum Gene Ther. 2013 Nov; 24(11):948-63.
Score: 0.021
-
Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo. Mol Ther. 2000 Dec; 2(6):649-56.
Score: 0.008